This innovation center invests in and incubates over 90 early-stage biopharmaceutical innovation enterprises, accelerating the transformation and commercialization process of new drug research and development from 0 to 1
Founded in Zhangjiang in 2008, Vivia Biotech is committed to providing one-stop comprehensive services to global innovative drug development enterprises, from early structure-based drug development to commercial drug delivery. In 2017, Vivian Biotech officially established the Vivian Biotech Innovation Center. Subsequently, after Vivia Biotech went public in Hong Kong in 2019, Vivia Innovation Center was identified as one of the company's three major business segments.
With years of accumulated experience and technological advantages in the field of new drug research and development, VBI provides a series of post investment value-added platform services, including investment and continuous optimization of research and development, site and logistics support, industry docking, investment and financing, based on the various needs of new drug research and development and the company's growth stage, accelerating the transformation and commercialization process of new drug research and development from 0 to 1. As of now, VBI has invested in and incubated over 90 early-stage biopharmaceutical innovation enterprises, including Weimou Biotechnology, Suozhi Biotechnology, and Bichen Pharmaceutical.
Professional team and professional services
The field of biopharmaceutical innovation gathers top-notch wisdom in the industry, so incubation investors who provide services for it also need high education, high quality, and senior industry background.
Dr. Dai Han, the head of VBI, has obtained a doctoral degree from the University of Texas Southwest Medical Center, as well as postdoctoral degrees from Harvard Medical School and Howard Hughes Institute of Medicine. I have served as a research and development, business expansion, and external innovation executive for multiple global pharmaceutical and biotechnology companies, successfully leading or jointly leading new drug discovery, preclinical development, translational medicine, and advancing biomarker research projects into clinical stages in multiple therapeutic fields, including oncology, immunology, metabolism, and neurological diseases.
The CRO technology services provided by VBI for innovative projects are not simply outsourced collaborations, but rather a service team composed of professional researchers from VIA Biotech, serving as external personnel to provide research and development services for these innovative projects. This ensures the quality of critical services and also brings VBI closer to innovative projects throughout the entire technical service process, enabling timely understanding of their needs and providing assistance.
Incubation mode promotes innovation
![This innovation center invests in and incubates over 90 early-stage biopharmaceutical innovation enterprises, accelerating the transformation and commercialization process of new drug research and development from 0 to 1](https://a5qu.com/upload/images/0a439d538af4c858d851097f216cd38a.jpg)
Among the innovative enterprises incubated by VBI in the past, biopharmaceutical enterprises accounted for the majority, with a focus on angel and pre A rounds in the investment stage. More than two-thirds of the enterprises were overseas, while the rest were in China. Most of these domestic innovative enterprises develop within VBI incubators, while overseas enterprises accept VBI virtual incubation.
After screening and entering the VBI incubation system, these innovative projects can obtain multiple software and hardware services. In terms of hardware, it includes VBI instruments and experimental equipment, physical space, and software, including the VBI technical service team. At the same time, VBI fully empowers innovative projects and enterprises by leveraging its industrial resource advantages and combining internal and external resources. VBI fully cooperates and exchanges with enterprises in incubation investment, helping them complete financing docking, cooperation with international pharmaceutical companies, negotiation of transactions, and recruitment of executives.
Continuous investment in industry improvement
In the current market reshaping period, the redistribution and restructuring of advantageous resources make it easier for incubating investors to find truly high-quality innovative projects. For these innovative projects and enterprises, incubation funds and resources are their common needs. Therefore, incubators like VBI with incubation investment experience and industrial resources will become the preferred place for these high-quality projects and enterprises.
Based on the trend of future industry development and the achievements of past investment incubation, VBI is planning to expand its incubation volume. Its site on Faraday Road is undergoing renovation and will be used in the future to accommodate more incubation projects and businesses.
At the same time, VBI has established two new funds, one for investment in device diagnostic projects and the other for investment in biopharmaceutical projects.
Dai Han stated that in the future, VBI and Vivia Biotech will shift their investment incubation focus to more diverse channels, establish more open cooperation and exchange platforms through annual summit meetings, Demo Day and other systematic activities, and continuously build and optimize the biopharmaceutical innovation ecosystem.
![This innovation center invests in and incubates over 90 early-stage biopharmaceutical innovation enterprises, accelerating the transformation and commercialization process of new drug research and development from 0 to 1](https://a5qu.com/upload/images/4e0b792458c247bc881b1c3370151234.jpg)
Text: Sun Lu
Data: District Science and Technology Promotion Center
*Reprinted from official WeChat account released by Pudong